29 stories mentioning ELVUpdated 2d ago
Every FINWIRES story that references ELV, newest first.
Elevance Health (ELV) has an average rating of overweight and mean price target of $380.29, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $346.34, Change: $+0.04, Percent Change: +0.01%
Elevance Health (ELV) has an average rating of overweight and mean price target of $380.29, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $346.34, Change: $+0.04, Percent Change: +0.01%
Elevance Health's (ELV) tone on the 2027 commercial pipeline was "constructive," RBC Capital Markets said in a note emailed Thursday.Analysts said that the company's Q1 core performance beat expectations, supported by favorable Medicare claims experience, a better-than-anticipated adjusted operating expense ratio, and early traction with Medicaid cost actions.RBC said it is still cautious on the stock as Elevance navigates an elevated Medicaid cost environment, ongoing Affordable Care Act risk-pool uncertainty, and 2027 Medicare Advantage rates, which continue to fall behind trend.Analysts lowered their Q2 adjusted earnings per share estimate for the company to $6.14 from $6.64. Analysts polled by FactSet expect $6.38.RBC, however, increased the full-year 2026 adjusted earnings per share estimate to $26.82 from $25.55. Analysts surveyed by FactSet expect $26.43.Analysts maintained a sector perform rating on the stock and a $358 price target.Price: $343.85, Change: $+15.65, Percent Change: +4.77%
Elevance Health (ELV) has an average rating of overweight and mean price target of $376.24, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $342.37, Change: $+14.17, Percent Change: +4.32%
Elevance Health (ELV) has an average rating of overweight and mean price target of $376.24, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $339.04, Change: $+10.84, Percent Change: +3.30%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target by $40 to $360, reflecting a 13.5x multiple of our 2026 EPS estimate, a small premium to ELV's three-year historical forward average of 12.7x but below the five-year average of 14.1x. We raise our 2026 EPS estimate to $26.77 from $26.05 and lower our 2027 EPS estimate to $29.08 from $29.56. Our negative fundamental outlook for the managed care sub-industry considers elevated medical cost trends, Affordable Care Act (ACA) subsidies expiration, Medicare reimbursement challenges, headwinds for Medicaid membership, and spending under the One Big Beautiful Bill Act (OBBBA). Though we look favorably on the Q1 outperformance and earnings guidance raise, we note that roughly $1.00 of the $1.25 EPS guidance increase (now set at $26.75 or greater) reflects nonrecurring net investment income. Shares yield 2.1%.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ELV reported Q1 2026 adjusted EPS of $12.58 vs. consensus of $11.97, beating by $1.77 (16.4%), while operating revenue grew 1.5% to $49.5B despite membership declining 0.9% to 45.4M. Benefit expense ratio of 86.8% remained elevated (up 40 bps), though operating expense ratio surged to 12.8% (up 210 bps) due to a $935M accrual for CMS noncompliance costs. We view the report as positive for ELV's gradual recovery toward prior profitability levels after recent challenges with higher medical costs and utilization. Management raised full-year EPS guidance to at least $26.75 from $25.50 previously. Strong cash flow enabled return of ~$1.5B to shareholders ($1.1B in buybacks, ~$376M in dividends) during the quarter, with $5.6B remaining on the share repurchase authorization. We see improvement in Medicare performance as encouraging, though membership trends reflect strategic repositioning efforts including a 15.8% decline in Medicare Advantage to 1.9M members.
The main US stock measures were trending higher in Wednesday's premarket activity after President Donald Trump extended the two-week US ceasefire with Iran, while traders await the latest round of corporate earnings, including results from Tesla (TSLA).The S&P 500 rose 0.6%, the Dow Jones Industrial Average increased 0.5% and the Nasdaq added 0.7% before the opening bell. The indexes finished Tuesday trading lower for the second consecutive session.In a social media post on Tuesday, Trump announced the extension of the two-week US ceasefire deal with Iran, citing a request by Pakistan's Prime Minister Shehbaz Sharif and Field Marshal Asim Munir. The truce was announced on April 7. The naval blockade of Iranian ports will continue, according to Trump."We have been asked to hold our attack on the country of Iran until such time as their leaders and representatives can come up with a unified proposal," Trump said in the post. "I have therefore directed our military to continue the blockade and, in all other respects, remain ready and able, and will therefore extend the ceasefire until such time as their proposal is submitted, and discussions are concluded, one way or the other."Iranian state news outlet Tasnim reported that negotiators from Tehran won't participate in further peace talks with their US counterparts, according to CNBC. US Vice President JD Vance's expected trip to Islamabad for peace talks with Iran has been called off, CNN reported, citing a White House official.West Texas Intermediate crude oil inclined 1.3% to $90.83 a barrel in premarket action, while Brent rose 1.1% to $99.56.The Trump administration is evaluating a potential extension of a maritime shipping waiver to make it easier to move oil and gasoline between US ports, Bloomberg News reported Wednesday, citing people familiar with the matter.Electric vehicle giant Tesla is scheduled to release its latest quarterly results after the markets close, along with International Business Machines (IBM) and Texas Instruments (TXN). GE Vernova (GEV), Philip Morris International (PM), AT&T (T), Boeing (BA), Boston Scientific (BSX) and Elevance Health (ELV) post earnings before the bell, among others.Intuitive Surgical (ISRG) shares advanced 2% pre-bell as the company lifted the full-year procedure growth outlook of its da Vinci robotic surgery system and reported better-than-expected first-quarter results. Advanced Micro Devices (AMD) gained 2%.Kevin Warsh said Tuesday that the Federal Reserve, under his leadership, would be independent from the White House, CNBC reported. Warsh, who is Trump's Fed chair nominee, made the remarks at his Senate Banking Committee confirmation hearing.Treasury yields were moving down before the open, with the two-year rate retreating 0.8 basis points to 3.77% and the 10-year rate off 1 basis point to 4.28%.Official data on Tuesday showed that retail sales last month logged the largest rise since March 2025 amid a surge in spending at gasoline stations as the Middle East conflict boosted energy prices.Wednesday's economic calendar has the weekly mortgage applications bulletin at 7 am ET, followed by the weekly EIA domestic petroleum inventories report at 10:30 am.Gold rose 1.1% to $4,769 per troy ounce, while bitcoin climbed 3.9% to $78,172.
Elevance Health (ELV) has an average rating of overweight and mean price target of $373.48, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $309.43, Change: $-3.92, Percent Change: -1.25%
Showing 21-29 of 29
